World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
20879
World Ranking
17232
National Ranking
8635

Overview

David R. Spriggs is affiliated with Massachusetts General Hospital in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology. A significant portion of their work focuses on subfields such as Molecular Biology, Oncology, Immunology, Radiology, Nuclear Medicine and Imaging, and Obstetrics and Gynecology.

The scientist's research topics include:

  • Monoclonal and Polyclonal Antibodies Research
  • Ovarian Cancer Diagnosis and Treatment
  • Glycosylation and Glycoproteins Research
  • Endometrial and Cervical Cancer Treatments
  • CAR-T Cell Therapy Research
  • Galectins and Cancer Biology
  • Cancer Immunotherapy and Biomarkers

Prominent publication venues where David R. Spriggs frequently publishes include:

  • Cancer Research
  • Gynecologic Oncology
  • Journal of Ovarian Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research

The recent papers by David R. Spriggs cover topics in oncology and immunotherapy with some of the titles and years as follows:

  • Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer, 2022, JAMA Oncology
  • Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition, 2021, Frontiers in Immunology
  • Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies, 2021, Scientific Reports
  • Galectins and Ovarian Cancer, 2020, Cancers
  • A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma, 2020, Journal of Translational Medicine

David R. Spriggs collaborates frequently with other researchers. Notable co-authors include:

  • Oladapo Yeku
  • Bo R. Rueda
  • Cesar M. Castro
  • Raj Kumar
  • Eric Eisenhauer

Best Publications

  • Detection of circulating tumor necrosis factor after endotoxin administration.

    Hamish R. Michie;Kirk R. Manogue;David R. Spriggs;Arthur Revhaug

  • Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

    Martee L. Hensley;Robert Maki;E. Venkatraman;Gennifer Geller

  • A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

    Carol Aghajanian;Steven Soignet;Don S. Dizon;Christine S. Pien

  • Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation

    Dennis E. Hallahan;David R. Spriggs;Michael A. Beckett;Donald W. Kufe

  • Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings.

    H R Michie;D R Spriggs;K R Manogue;M L Sherman

  • Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

    David R. Spriggs;Matthew L. Sherman;Hamish Michie;Kristina A. Arthur

  • IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo

    Mythili Koneru;Terence J. Purdon;David Spriggs;Susmith Koneru

  • Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha

    Dominik B. Dubravec;David R. Spriggs;John A. Mannick;Mary L. Rodrick

  • Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.

    Oladapo O. Yeku;Terence J. Purdon;Mythili Koneru;David Spriggs

  • BRCA1 Up-Regulation Is Associated with Repair-mediated Resistance to cis-Diamminedichloroplatinum(II)

    Amreen Husain;Guoshun He;Ennapadam S. Venkatraman;David R. Spriggs

  • Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

    Paul Sabbatini;Takemasa Tsuji;Luis Ferran;Erika Ritter

  • Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.

    D Fennelly;C Aghajanian;F Shapiro;C O'Flaherty

  • A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16 ecto directed chimeric antigen receptors for recurrent ovarian cancer

    Mythili Koneru;Mythili Koneru;Roisin O’Cearbhaill;Roisin O’Cearbhaill;Swati Pendharkar;David R Spriggs;David R Spriggs

  • Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.

    M L Sherman;D R Spriggs;K A Arthur;K Imamura

  • Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

    Xingxing Zang;Peggy S Sullivan;Robert A Soslow;Rebecca Waitz

  • Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors

    A. Craig Lockhart;Mace L. Rothenberg;Jakob Dupont;Wendy Cooper

  • Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.

    Robert A Soslow;Guangming Han;Kay J Park;Karuna Garg

  • Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma : Results of a prospective study

    Martee L. Hensley;Nicole Ishill;Robert Soslow;Joseph Larkin

  • BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

    Rachel N. Grisham;Gopa Iyer;Karuna Garg;Deborah DeLair

  • Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.

    H H Bailey;R T Mulcahy;K D Tutsch;R Z Arzoomanian

Frequent Co-Authors

Carol Aghajanian
Carol Aghajanian Memorial Sloan Kettering Cancer Center
Donald Kufe
Donald Kufe Harvard University
George Wilding
George Wilding University of Wisconsin–Madison
Renier J. Brentjens
Renier J. Brentjens Roswell Park Cancer Institute
Joan H. Schiller
Joan H. Schiller University of Virginia
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Gary K. Schwartz
Gary K. Schwartz Memorial Sloan Kettering Cancer Center
Jason A. Koutcher
Jason A. Koutcher Memorial Sloan Kettering Cancer Center
Charles A. Dinarello
Charles A. Dinarello University of Colorado Anschutz Medical Campus
Nancy E. Kemeny
Nancy E. Kemeny Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring alternative healthcare careers or flexible study options, there are many related online degrees to consider. Medical support roles are in high demand, and starting with medical coding and billing classes online with financial aid is an accessible way to enter the medical field without committing to a long degree.

For those interested in nursing, finding nursing schools that don't require teas test can simplify the admissions process and help you start your career sooner. If you already have a background in nursing, pursuing adn to msn bridge programs provides a streamlined path to advanced practice roles and leadership positions in healthcare.

Additionally, an online healthcare administration degree is ideal if you’re more interested in the management and policy aspects of the medical industry, opening doors to leadership jobs in hospitals and clinics. These related degrees offer flexible, practical alternatives for building a rewarding career in healthcare.

Best Scientists Citing David R. Spriggs

Trending Scientists

Recently Published Articles